HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Boyadjieva, N. I. Articles by Sarkar, D. K. Search for Related Content PubMed PubMed Citation Articles by Boyadjieva, N. I. Articles by Sarkar, D. K.

Opioid Antagonist Naltrexone Disrupts Feedback Interaction between µ and Opioid Receptors in Splenocytes to Prevent Alcohol Inhibition of NK Cell Function¹

Program of Endocrinology, Center of Alcohol Studies, Department of Animal Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901

Naltrexone, an opioid antagonist, has been used in clinical trials to treat alcoholism. As the opioid peptides -endorphin and enkephalin increase splenic NK cell function in laboratory animals, it is anticipated that naltrexone treatment will cause immunosuppression. However, we report in this study that chronic naltrexone administration in laboratory rats increases the cytolytic activity of NK cells. It also prevents alcohol’s suppressive effect on these cells. We identified that, in the splenocytes, opioid receptor expression is tightly controlled by negative feedback regulation of µ opioid receptors. Naltrexone disrupts this feedback control by reducing µ opioid receptor function, thereby up-regulating opioid receptor binding, which results in an enhanced NK cell cytolytic response to opioid receptor ligands. We conclude that naltrexone, which has been shown to be a promising agent for the clinical management of alcoholism, may have potential use in the treatment of immune deficiency in alcoholic and nonalcoholic patients.